79,404 XNAS Volume
XNAS 04 Apr, 2025 11:05 AM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Lynne Sullivan | CFO & Head of Corp. Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2025 | 65,000 | 120,772 (0%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Lynne Sullivan | CFO & Head of Corp. Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2025 | 106,000 | 106,000 | - | - | Stock Option (Right to Buy) | |
| Anirvan Ghosh | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2025 | 286,000 | 286,000 | - | - | Stock Option (Right to Buy) | |
| Anirvan Ghosh | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2025 | 175,000 | 250,251 (0%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Alexander Hieu Nguyen | CLO and Head of Ops | Sale of securities on an exchange or to another person at price $ 1.16 per share. | 27 Mar 2025 | 1,954 | 22,605 (0%) | 0% | 1.2 | 2,267 | Common Stock, $0.0001 par value |
| Alexander Hieu Nguyen | CLO and Head of Ops | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2025 | 73,000 | 73,000 | - | - | Stock Option (Right to Buy) | |
| Alexander Hieu Nguyen | CLO and Head of Ops | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2025 | 44,000 | 66,605 (0%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Yehia Hashad | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2025 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Lynne Sullivan | CFO & Head of Corp. Dev. | Sale of securities on an exchange or to another person at price $ 2.23 per share. | 04 Feb 2025 | 153 | 55,772 (0%) | 0% | 2.2 | 341 | Common Stock, $0.0001 par value |
| Anirvan Ghosh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.23 per share. | 04 Feb 2025 | 642 | 75,251 (0%) | 0% | 2.2 | 1,432 | Common Stock, $0.0001 par value |
| Alexander Hieu Nguyen | CLO and Head of Ops | Sale of securities on an exchange or to another person at price $ 2.23 per share. | 04 Feb 2025 | 164 | 24,559 (0%) | 0% | 2.2 | 366 | Common Stock, $0.0001 par value |
| Lynne Sullivan | CFO & Head of Corp. Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2025 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Anirvan Ghosh | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2025 | 450,000 | 450,000 | - | - | Stock Option (Right to Buy) | |
| Alexander Hieu Nguyen | CLO and Head of Ops | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2025 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Lynne Sullivan | CFO & Head of Corp. Dev. | Sale of securities on an exchange or to another person at price $ 1.29 per share. | 04 Nov 2024 | 136 | 55,925 (0%) | 0% | 1.3 | 175 | Common Stock, $0.0001 par value |
| Anirvan Ghosh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.29 per share. | 04 Nov 2024 | 432 | 75,893 (0%) | 0% | 1.3 | 557 | Common Stock, $0.0001 par value |
| Alexander Hieu Nguyen | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 1.29 per share. | 04 Nov 2024 | 149 | 24,723 (0%) | 0% | 1.3 | 192 | Common Stock, $0.0001 par value |
| Lynne Sullivan | CFO & Head of Corp. Dev. | Sale of securities on an exchange or to another person at price $ 1.53 per share. | 02 Aug 2024 | 139 | 56,061 (0%) | 0% | 1.5 | 213 | Common Stock, $0.0001 par value |
| Anirvan Ghosh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.53 per share. | 02 Aug 2024 | 604 | 76,325 (0%) | 0% | 1.5 | 924 | Common Stock, $0.0001 par value |
| Alexander Hieu Nguyen | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 1.53 per share. | 02 Aug 2024 | 154 | 24,872 (0%) | 0% | 1.5 | 236 | Common Stock, $0.0001 par value |
| Lynne Sullivan | CFO & Head of Corp. Dev. | Sale of securities on an exchange or to another person at price $ 1.40 per share. | 25 Jun 2024 | 324 | 32,685 (0%) | 0% | 1.4 | 454 | Common Stock, $0.0001 par value |
| Anirvan Ghosh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.40 per share. | 25 Jun 2024 | 1,214 | 76,929 (0%) | 0% | 1.4 | 1,700 | Common Stock, $0.0001 par value |
| Alexander Hieu Nguyen | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 1.40 per share. | 25 Jun 2024 | 78 | 25,026 (0%) | 0% | 1.4 | 109 | Common Stock, $0.0001 par value |
| Paul L. Berns | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Keith R. Leonard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Camille D. Samuels | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Nathaniel E. David | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Margo R. Roberts | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Michael P. Samar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Anirvan Ghosh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.55 per share. | 02 May 2024 | 603 | 78,143 (0%) | 0% | 1.6 | 935 | Common Stock, $0.0001 par value |
| Alexander Hieu Nguyen | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 20,000 | 25,104 (0%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Alexander Hieu Nguyen | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Ghosh Anirvan | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.71 per share. | 02 Feb 2024 | 680 | 78,746 (0%) | 0% | 1.7 | 1,163 | Common Stock, $0.0001 par value |
| Anirvan Ghosh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.71 per share. | 30 Jan 2024 | 1,183 | 79,426 (0%) | 0% | 1.7 | 2,023 | Common Stock, $0.0001 par value |
| Anirvan Ghosh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.94 per share. | 02 Aug 2023 | 581 | 83,468 (0%) | 0% | 2.9 | 1,708 | Common Stock, $0.0001 par value |
| Anirvan Ghosh | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.86 per share. | 31 Jul 2023 | 1,020 | 84,049 (0%) | 0% | 2.9 | 2,917 | Common Stock, $0.0001 par value |
| Anirvan Ghosh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.20 per share. | 26 Jun 2023 | 1,177 | 85,069 (0%) | 0% | 3.2 | 3,766 | Common Stock, $0.0001 par value |
| Paul L. Berns | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2023 | 6,000 | 6,000 | - | - | Stock Option (Right to Buy) | |
| Keith R. Leonard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2023 | 6,000 | 6,000 | - | - | Stock Option (Right to Buy) | |
| Camille D. Samuels | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2023 | 6,000 | 6,000 | - | - | Stock Option (Right to Buy) | |
| Nathaniel E. David | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2023 | 6,000 | 6,000 | - | - | Stock Option (Right to Buy) | |
| Margo R. Roberts | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2023 | 6,000 | 6,000 | - | - | Stock Option (Right to Buy) | |
| Michael P. Samar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2023 | 6,000 | 6,000 | - | - | Stock Option (Right to Buy) | |
| Anirvan Ghosh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.39 per share. | 14 Jun 2023 | 1,212 | 86,246 (0%) | 0% | 3.4 | 4,109 | Common Stock, $0.0001 par value |
| Anirvan Ghosh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.17 per share. | 02 May 2023 | 588 | 87,458 (0%) | 0% | 2.2 | 1,276 | Common Stock, $0.0001 par value |
| Anirvan Ghosh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.15 per share. | 01 May 2023 | 1,020 | 88 (0%) | 0% | 2.2 | 2,193 | Common Stock, $0.0001 par value |
| Jamie Dananberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.70 per share. | 31 Mar 2023 | 420 | 62,817 (0%) | 0% | 1.7 | 714 | Common Stock, $0.0001 par value |
| Anirvan Ghosh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.70 per share. | 31 Mar 2023 | 1,959 | 89,066 (0%) | 0% | 1.7 | 3,330 | Common Stock, $0.0001 par value |
| Jamie Dananberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.00 per share. | 14 Mar 2023 | 1,005 | 63,237 (0%) | 0% | 4 | 4,020 | Common Stock, $0.0001 par value |
| Anirvan Ghosh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 4.00 per share. | 14 Mar 2023 | 1,210 | 91,025 (0%) | 0% | 4 | 4,840 | Common Stock, $0.0001 par value |
| Jamie Dananberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 4.84 per share. | 02 Feb 2023 | 863 | 64,242 (0%) | 0% | 4.8 | 4,177 | Common Stock, $0.0001 par value |
| Anirvan Ghosh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 4.84 per share. | 02 Feb 2023 | 2,573 | 92,235 (0%) | 0% | 4.8 | 12,453 | Common Stock, $0.0001 par value |
| Anirvan Ghosh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 4.45 per share. | 30 Jan 2023 | 1,140 | 94,808 (0%) | 0% | 4.5 | 5,073 | Common Stock, $0.0001 par value |
| Jamie Dananberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 2.85 per share. | 14 Dec 2022 | 1,016 | 65,105 (0%) | 0% | 2.9 | 2,896 | Common Stock, $0.0001 par value |
| Anirvan Ghosh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.85 per share. | 14 Dec 2022 | 1,274 | 95,948 (0%) | 0% | 2.9 | 3,631 | Common Stock, $0.0001 par value |
| Lynne Sullivan | CFO & Head of Corp. Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Lynne Sullivan | CFO & Head of Corp. Dev. | Other type of transaction at price $ 6.89 per share. | 18 Nov 2022 | 925 | 33,009 (0%) | 0% | 6.9 | 6,373 | Common Stock, $0.0001 par value |
| Jamie Dananberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2022 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Anirvan Ghosh | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2022 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Alexander Hieu Nguyen | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Nov 2022 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Anirvan Ghosh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.40 per share. | 03 Nov 2022 | 1,099 | 97,222 (0%) | 0% | 2.4 | 2,638 | Common Stock, $0.0001 par value |
| Jamie Dananberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 0.48 per share. | 14 Sep 2022 | 10,923 | 661,213 (1%) | 0% | 0.5 | 5,243 | Common Stock, $0.0001 par value |
| Anirvan Ghosh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 0.48 per share. | 14 Sep 2022 | 13,706 | 983,210 (2%) | 0% | 0.5 | 6,579 | Common Stock, $0.0001 par value |
| Anirvan Ghosh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 0.67 per share. | 01 Aug 2022 | 10,446 | 996,916 (2%) | 0% | 0.7 | 6,999 | Common Stock, $0.0001 par value |
| Jamie Dananberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 0.59 per share. | 27 Jun 2022 | 4,398 | 672,136 (1%) | 0% | 0.6 | 2,595 | Common Stock, $0.0001 par value |
| Anirvan Ghosh | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 0.59 per share. | 27 Jun 2022 | 12,149 | 1,007,362 (2%) | 0% | 0.6 | 7,168 | Common Stock, $0.0001 par value |
| Paul L. Berns | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Keith R. Leonard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Camille D. Samuels | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Nathaniel E. David | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Margo R. Roberts | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Michael P. Samar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2022 | 2,055 | 2,055 | - | - | Stock Option (Right to Buy) | |
| Jamie Dananberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 0.62 per share. | 21 Jun 2022 | 3,697 | 676,534 (1%) | 0% | 0.6 | 2,292 | Common Stock, $0.0001 par value |
| Jamie Dananberg | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.63 per share. | 14 Jun 2022 | 10,530 | 680,231 (1%) | 0% | 0.6 | 6,634 | Common Stock, $0.0001 par value |
| Anirvan Ghosh | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.63 per share. | 14 Jun 2022 | 12,683 | 1,019,511 (2%) | 0% | 0.6 | 7,990 | Common Stock, $0.0001 par value |
| Michael P. Samar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Anirvan Ghosh | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.88 per share. | 02 May 2022 | 7,729 | 1,032,194 (2%) | 0% | 0.9 | 6,802 | Common Stock, $0.0001 par value |
| Jamie Dananberg | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.14 per share. | 31 Mar 2022 | 4,188 | 690,761 (1%) | 0% | 1.1 | 4,774 | Common Stock, $0.0001 par value |
| Anirvan Ghosh | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.14 per share. | 31 Mar 2022 | 14,472 | 1,039,923 (2%) | 0% | 1.1 | 16,498 | Common Stock, $0.0001 par value |
| Jamie Dananberg | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.88 per share. | 14 Mar 2022 | 10,581 | 694,949 (1%) | 0% | 0.9 | 9,311 | Common Stock, $0.0001 par value |
| Anirvan Ghosh | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.88 per share. | 14 Mar 2022 | 9,272 | 1,054,395 (2%) | 0% | 0.9 | 8,159 | Common Stock, $0.0001 par value |
| Lynne Sullivan | CFO & Head of Corp. Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 50,000 | 326,785 (0%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Lynne Sullivan | CFO & Head of Corp. Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Jamie Dananberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 183,333 | 183,333 | - | - | Stock Option (Right to Buy) | |
| Jamie Dananberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 45,833 | 705,530 (1%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Anirvan Ghosh | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 566,667 | 566,667 | - | - | Stock Option (Right to Buy) | |
| Anirvan Ghosh | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 141,667 | 1,063,667 (2%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Alexander Hieu Nguyen | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 183,333 | 183,333 | - | - | Stock Option (Right to Buy) | |
| Alexander Hieu Nguyen | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 45,833 | 51,041 (0%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Jamie Dananberg | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.63 per share. | 14 Dec 2021 | 10,614 | 659,697 (1%) | 0% | 1.6 | 17,301 | Common Stock, $0.0001 par value |
| Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Paul L. Berns | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Keith R. Leonard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Camille D. Samuels | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Nathaniel David | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 11,918 | 11,918 | - | - | Stock Option (Right to Buy) | |
| Kristina Burow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Margo R. Roberts | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Lynne Sullivan | CFO & Head of Corp. Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 123,333 | 123,333 | - | - | Stock Option (Right to Buy) | |
| Lynne Sullivan | CFO & Head of Corp. Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 30,833 | 270,833 (0%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Jamie Dananberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Jamie Dananberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 25,000 | 710,875 (1%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Anirvan Ghosh | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 72,000 | 922,000 (2%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Anirvan Ghosh | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 290,000 | 290,000 | - | - | Stock Option (Right to Buy) | |
| Alexander Hieu Nguyen | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 5,208 | 5,208 (0%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Alexander Hieu Nguyen | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 20,833 | 20,833 | - | - | Stock Option (Right to Buy) | |
| Jamie Dananberg | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.18 per share. | 21 Jun 2021 | 3,515 | 685,875 (1%) | 0% | 4.2 | 14,693 | Common Stock, $0.0001 par value |
| Jamie Dananberg | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.73 per share. | 30 Mar 2021 | 2,829 | 689,390 (1%) | 0% | 5.7 | 16,210 | Common Stock, $0.0001 par value |
| Alexander Hieu Nguyen | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2021 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Nathaniel David | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Anirvan Ghosh | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 250,000 | 850,000 (1%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Anirvan Ghosh | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Nathaniel David | Director, President | Sale of securities on an exchange or to another person at price $ 5.24 per share. | 16 Dec 2020 | 1,700,000 | 624,703 (1%) | 3% | 5.2 | 8,908,000 | Common Stock, $0.0001 par value |
| Lynne Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2020 | 240,000 | 240,000 (0%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Jamie Dananberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2020 | 240,000 | 692,219 (1%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Alexander Azoy | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2020 | 135,000 | 135,000 (0%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Anirvan Ghosh | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2020 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Anirvan Ghosh | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2020 | 300,000 | 600,000 (1%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Lynne Sullivan | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2020 | 240,000 | 240,000 | - | - | Stock Option (Right to Buy) | |
| Keith R. Leonard | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.67 per share. | 22 Jun 2020 | 4,711 | 89,546 (0%) | 0% | 9.7 | 45,555 | Common Stock, $0.0001 par value |
| Tamara Tompkins | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.67 per share. | 22 Jun 2020 | 2,483 | 42,847 (0%) | 0% | 9.7 | 24,011 | Common Stock, $0.0001 par value |
| Nathaniel David | Director, President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.67 per share. | 22 Jun 2020 | 2,483 | 2,324,703 (5%) | 0% | 9.7 | 24,011 | Common Stock, $0.0001 par value |
| Daniel G. Marquess | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.67 per share. | 22 Jun 2020 | 2,483 | 380,690 (0%) | 0% | 9.7 | 24,011 | Common Stock, $0.0001 par value |
| Robert C. Goeltz | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.67 per share. | 22 Jun 2020 | 2,483 | 161,027 (0%) | 0% | 9.7 | 24,011 | Common Stock, $0.0001 par value |
| Jamie Dananberg | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.67 per share. | 22 Jun 2020 | 2,483 | 452,219 (0%) | 0% | 9.7 | 24,011 | Common Stock, $0.0001 par value |
| Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Robert T. Nelsen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Paul L. Berns | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Keith R. Leonard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Camille D. Samuels | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Kristina Burow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Margo R. Roberts | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| David L. Lacey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Nathaniel David | Director, President | Purchase of securities on an exchange or from another person at price $ 8.90 per share. | 05 Jun 2020 | 3,200 | 2,327,186 (5%) | 0% | 8.9 | 28,478 | Common Stock, $0.0001 par value |
| Tamara Tompkins | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2020 | 98,490 | 98,490 | - | - | Stock Option (Right to Buy) | |
| Tamara Tompkins | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2020 | 24,255 | 45,330 (0%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Nathaniel David | Director, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2020 | 24,255 | 2,323,986 (5%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Nathaniel David | Director, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2020 | 98,490 | 98,490 | - | - | Stock Option (Right to Buy) | |
| Daniel G. Marquess | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2020 | 98,490 | 98,490 | - | - | Stock Option (Right to Buy) | |
| Daniel G. Marquess | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2020 | 24,255 | 381,297 (0%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2020 | 118,188 | 118,188 | - | - | Stock Option (Right to Buy) | |
| Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2020 | 29,106 | 163,510 (0%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Jamie Dananberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2020 | 98,490 | 98,490 | - | - | Stock Option (Right to Buy) | |
| Jamie Dananberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2020 | 24,255 | 454,702 (0%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Anirvan Ghosh | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2020 | 30,000 | 30,000 (0%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Anirvan Ghosh | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2020 | 150,000 | 300,000 (0%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Anirvan Ghosh | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2020 | 800,000 | 800,000 | - | - | Stock Option (Right to Buy) | |
| Anirvan Ghosh | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2020 | 120,000 | 150,000 (0%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Keith R. Leonard | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2019 | 383,475 | 0 (0%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Keith R. Leonard | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2019 | 116,525 | 94,257 (0%) | 0% | 0 | Common Stock, $0.0001 par value | |
| Keith R. Leonard | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2019 | 500,000 | 500,000 (1%) | 1% | 0 | Common Stock, $0.0001 par value | |
| Keith R. Leonard | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Sep 2019 | 35,525 | 35,525 | - | - | Stock Option (Right to Buy) | |
| Tamara Tompkins | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Sep 2019 | 19,068 | 19,068 | - | - | Stock Option (Right to Buy) | |
| Nathaniel E. David | Director, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Sep 2019 | 27,825 | 27,825 | - | - | Stock Option (Right to Buy) | |
| Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Sep 2019 | 28,814 | 28,814 | - | - | Stock Option (Right to Buy) | |
| Graham K. Cooper | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Robert Taylor Nelsen | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Paul L. Berns | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Keith R. Leonard | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 40,000 | 210,782 (0%) | 0% | 0 | Common Stock | |
| Keith R. Leonard | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 260,000 | 260,000 | - | - | Stock Option (Right to Buy) | |
| Camille D. Samuels | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Tamara Tompkins | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 21,075 | 21,075 (0%) | 0% | 0 | Common Stock | |
| Tamara Tompkins | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 106,800 | 106,800 | - | - | Stock Option (Right to Buy) | |
| Nathaniel E. David | Director, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 106,800 | 106,800 | - | - | Stock Option (Right to Buy) | |
| Nathaniel E. David | Director, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 21,075 | 2,299,731 (5%) | 0% | 0 | Common Stock | |
| Kristina M. Burow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Margo R. Roberts | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Daniel G. Marquess | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 21,075 | 357,041 (0%) | 0% | 0 | Common Stock | |
| Daniel G. Marquess | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 106,800 | 106,800 | - | - | Stock Option (Right to Buy) | |
| Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 116,850 | 116,850 | - | - | Stock Option (Right to Buy) | |
| Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 21,075 | 124,404 (0%) | 0% | 0 | Common Stock | |
| David L. Lacey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Jamie Dananberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 106,800 | 106,800 | - | - | Stock Option (Right to Buy) | |
| Jamie Dananberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2019 | 21,075 | 430,447 (0%) | 0% | 0 | Common Stock | |
| Keith R. Leonard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jun 2019 | 20,000 | 1,364,100 | - | - | Stock Option (Right to Buy) | |
| Keith R. Leonard | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.40 per share. | 19 Jun 2019 | 20,000 | 170,782 (0%) | 0% | 3.4 | 68,000 | Common Stock |
| Margo R. Roberts | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2018 | 50,661 | 50,661 | - | - | Stock Option (right to buy) | |
| Robert C. Goeltz | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.43 per share. | 10 Oct 2018 | 5,000 | 101,348 (0%) | 0% | 3.4 | 17,150 | Common Stock, $0.0001 par value |
| Robert C. Goeltz | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Oct 2018 | 5,000 | 120,620 | - | - | Stock Option (Right to Buy) | |
| Robert T. Nelsen | Director, Ten Percent Owner | 07 May 2018 | 195,672 | 1,682,417 (4%) | 0% | 0 | Common Stock | ||
| Robert T. Nelsen | Director, Ten Percent Owner | 07 May 2018 | 2,030,625 | 0 | - | - | Series A-1 Preferred Stock | ||
| Robert T. Nelsen | Director, Ten Percent Owner | 07 May 2018 | 4,228,432 | 0 | - | - | Series A-2 Preferred Stock | ||
| Robert T. Nelsen | Director, Ten Percent Owner | 07 May 2018 | 2,067,160 | 0 | - | - | Series B Preferred Stock | ||
| Robert T. Nelsen | Director, Ten Percent Owner | 07 May 2018 | 1,486,745 | 0 | - | - | Series B Preferred Stock | ||
| Robert T. Nelsen | Director, Ten Percent Owner | 07 May 2018 | 195,672 | 0 | - | - | Series C Preferred Stock | ||
| Robert T. Nelsen | Director, Ten Percent Owner | 07 May 2018 | 2,030,625 | 2,070,172 (4%) | 4% | 0 | Common Stock | ||
| Robert T. Nelsen | Director, Ten Percent Owner | 07 May 2018 | 2,067,160 | 8,365,764 (19%) | 4% | 0 | Common Stock | ||
| Robert T. Nelsen | Director, Ten Percent Owner | 07 May 2018 | 1,486,745 | 1,486,745 (3%) | 3% | 0 | Common Stock | ||
| Robert T. Nelsen | Director, Ten Percent Owner | 07 May 2018 | 4,228,432 | 6,298,604 (15%) | 10% | 0 | Common Stock | ||
| Paul L. Berns | None | 07 May 2018 | 3,261 | 3,261 (0%) | 0% | 0 | Common Stock | ||
| Paul L. Berns | None | 07 May 2018 | 3,261 | 0 | - | - | Series C Preferred Stock | ||
| Keith R. Leonard | Director, Chief Executive Officer | 07 May 2018 | 383,475 | 383,475 (0%) | 0% | 0 | Common Stock | ||
| Keith R. Leonard | Director, Chief Executive Officer | 07 May 2018 | 1,630 | 150,782 (0%) | 0% | 0 | Common Stock | ||
| Keith R. Leonard | Director, Chief Executive Officer | 07 May 2018 | 148,448 | 148,448 (0%) | 0% | 0 | Common Stock | ||
| Keith R. Leonard | Director, Chief Executive Officer | 07 May 2018 | 1,630 | 0 | - | - | Series C Preferred Stock | ||
| Keith R. Leonard | Director, Chief Executive Officer | 07 May 2018 | 148,448 | 0 | - | - | Series B Preferred Stock | ||
| Keith R. Leonard | Director, Chief Executive Officer | 07 May 2018 | 383,475 | 0 | - | - | Series B Preferred Stock | ||
| Nathaniel David | Director, President | 07 May 2018 | 222,148 | 2,277,026 (5%) | 0% | 0 | Common Stock | ||
| Nathaniel David | Director, President | 07 May 2018 | 1,630 | 0 | - | - | Series C Preferred Stock | ||
| Nathaniel David | Director, President | 07 May 2018 | 222,148 | 0 | - | - | Series B Preferred Stock | ||
| Nathaniel David | Director, President | 07 May 2018 | 1,074,032 | 0 | - | - | Series A-2 Preferred Stock | ||
| Nathaniel David | Director, President | 07 May 2018 | 1,630 | 2,278,656 (5%) | 0% | 0 | Common Stock | ||
| Nathaniel David | Director, President | 07 May 2018 | 1,074,032 | 2,054,878 (4%) | 2% | 0 | Common Stock | ||
| Kristina Burow | None | 07 May 2018 | 195,672 | 0 | - | - | Series C Preferred Stock | ||
| Kristina Burow | None | 07 May 2018 | 1,486,745 | 0 | - | - | Series B Preferred Stock | ||
| Kristina Burow | None | 07 May 2018 | 2,067,160 | 0 | - | - | Series B Preferred Stock | ||
| Kristina Burow | None | 07 May 2018 | 4,228,432 | 0 | - | - | Series A-2 Preferred Stock | ||
| Kristina Burow | None | 07 May 2018 | 2,067,160 | 8,365,764 (19%) | 4% | 0 | Common Stock | ||
| Kristina Burow | None | 07 May 2018 | 1,486,745 | 1,486,745 (3%) | 3% | 0 | Common Stock | ||
| Kristina Burow | None | 07 May 2018 | 2,030,625 | 0 | - | - | Series A-1 Preferred Stock | ||
| Kristina Burow | None | 07 May 2018 | 2,030,625 | 2,070,172 (4%) | 4% | 0 | Common Stock | ||
| Kristina Burow | None | 07 May 2018 | 4,228,432 | 6,298,604 (15%) | 10% | 0 | Common Stock | ||
| Kristina Burow | None | 07 May 2018 | 195,672 | 1,682,417 (4%) | 0% | 0 | Common Stock | ||
| Robert C. Goeltz | Chief Financial Officer | 07 May 2018 | 1,630 | 0 | - | - | Series C Preferred Stock | ||
| Robert C. Goeltz | Chief Financial Officer | 07 May 2018 | 1,630 | 96,348 (0%) | 0% | 0 | Common Stock | ||
| Jamie Dananberg | Chief Medical Officer | 07 May 2018 | 74,048 | 0 | - | - | Series B Preferred Stock | ||
| Jamie Dananberg | Chief Medical Officer | 07 May 2018 | 1,630 | 0 | - | - | Series C Preferred Stock | ||
| Jamie Dananberg | Chief Medical Officer | 07 May 2018 | 74,048 | 407,742 (0%) | 0% | 0 | Common Stock | ||
| Jamie Dananberg | Chief Medical Officer | 07 May 2018 | 1,630 | 409,372 (0%) | 0% | 0 | Common Stock | ||
| Graham K. Cooper | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2018 | 10,169 | 10,169 | - | - | Stock Option (Right to Buy) | |
| Robert T. Nelsen | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2018 | 40,678 | 40,678 | - | - | Stock Option (Right to Buy) | |
| Keith R. Leonard | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2018 | 67,797 | 67,797 | - | - | Stock Option (Right to Buy) | |
| Camille D. Samuels | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2018 | 40,678 | 40,678 | - | - | Stock Option (Right to Buy) | |
| Tamara Tompkins | Corporate Secretary and GC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2018 | 30,508 | 30,508 | - | - | Stock Option (Right to Buy) | |
| Nathaniel David | Director, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2018 | 47,458 | 47,458 | - | - | Stock Option (Right to Buy) | |
| Kristina Burow | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2018 | 40,678 | 40,678 | - | - | Stock Option (Right to Buy) | |
| Daniel G. Marquess | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2018 | 30,508 | 30,508 | - | - | Stock Option (Right to Buy) | |
| Robert C. Goeltz | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2018 | 30,508 | 30,508 | - | - | Stock Option (Right to Buy) | |
| Jamie Dananberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2018 | 30,508 | 30,508 | - | - | Stock Option (Right to Buy) |